Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus

Introduction to Alternative Treatments

• For patients with rheumatoid arthritis or systemic lupus erythematosus who cannot take hydroxychloroquine, the primary alternatives are sulfasalazine, methotrexate, or leflunomide, with the specific choice depending on disease severity and patient characteristics 1

First-Line Alternatives

• Sulfasalazine is the first-line alternative to hydroxychloroquine for patients with low disease activity RA 1
• Methotrexate is conditionally recommended over leflunomide due to greater dosing flexibility and lower cost 1

Treatment Recommendations

• Methotrexate monotherapy is strongly recommended as the first-line treatment 2, 1
• Leflunomide can be used if methotrexate is contraindicated 1
• Combination therapy options, such as triple therapy (methotrexate + sulfasalazine + another DMARD) for patients with inadequate response to monotherapy, are available 3
• Biologic DMARDs (TNF inhibitors, abatacept, tocilizumab, rituximab) can be used for patients with inadequate response to conventional DMARDs 3

Treatment for SLE Patients

• Methotrexate is particularly effective for skin and joint manifestations in SLE patients 4
• Mycophenolate mofetil is especially effective for lupus nephritis in SLE patients 4
• Azathioprine can be used for maintenance therapy in SLE patients 4
• Belimumab can be used for patients with active disease despite standard therapy 4
• Rituximab can be used particularly for refractory cases in SLE patients 4

Disease Severity Assessment

• Low disease activity: Consider sulfasalazine first 1
• Moderate-to-high disease activity: Consider methotrexate first 1

Organ Involvement Considerations

• Predominant joint symptoms: Methotrexate or leflunomide can be used 1
• Lupus nephritis: Mycophenolate mofetil or cyclophosphamide can be used 4
• Skin manifestations: Methotrexate or mycophenolate mofetil can be used 4

Medication Administration and Monitoring

• Starting dose of methotrexate: 15 mg weekly within 4-6 weeks 1
• Oral administration is preferred initially over subcutaneous 1
• Monitor for hepatotoxicity, bone marrow suppression, and pulmonary toxicity 1
• Regular clinical assessment of disease activity (every 1-3 months until target achieved) 1
• Laboratory monitoring specific to each medication:

General Treatment Recommendations

• Don't delay treatment - Early aggressive treatment improves long-term outcomes 1
• Avoid long-term glucocorticoids - Strong recommendation against longer-term (≥3 months) glucocorticoid therapy due to significant toxicity 1
• Don't undertreat - Inadequate disease control leads to irreversible joint damage and organ dysfunction 1
• Don't forget regular monitoring - Each medication requires specific monitoring for potential toxicities 1